Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Canbas Co., Ltd. (Japan)
Homepage:
canbas.co.jp
Alternate names:
Canbas,
Canbas Co., Ltd.,
株式会社キャンバス
ROR:
01v85d902
OpenAlex ID:
I4405264408
G2 checkpoint abrogators as anticancer drugs
2004
·
Takumi Kawabe
·
Molecular Cancer Therapeutics
·
413
CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity
2011
·
Keiichi Sakakibara
, Naoya Saito
, et al.
·
Blood
·
136
Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint
2007
·
Shi-Ken Sha
, Takuji Sato
, et al.
·
Molecular Cancer Therapeutics
·
52
PDF
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma
2014
·
L.M. Krug
, A.J. Wozniak
, et al.
·
Lung Cancer
·
33
CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
2014
·
Naoya Saito
, Keiichi Sakakibara
, et al.
·
Molecular Cancer Therapeutics
·
29
Boromycin Abrogates Bleomycin-induced G2 Checkpoint
2004
·
MASAYOSHI ARAI
, YUKIO KOIZUMI
, et al.
·
The Journal of Antibiotics
·
22
PDF
Selective inhibition of bleomycin-induced G2 cell cycle checkpoint by simaomicin α
2004
·
Masayoshi Arai
, Hitoshi Sato
, et al.
·
Biochemical and Biophysical Research Communications
·
21
CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding
2017
·
Naoya Saito
, Naoki Mine
, et al.
·
Oncotarget
·
20
PDF
CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice
2017
·
Keiichi Sakakibara
, Takuji Sato
, et al.
·
Oncotarget
·
17
PDF
Identification of U83836E as a γ-glutamylcyclotransferase inhibitor that suppresses MCF7 breast cancer xenograft growth
2021
·
Hiromi Ii
, Yukie Nohara
, et al.
·
Biochemical and Biophysical Research Communications
·
14
PDF
Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501-binding site
2011
·
Yuki Matsumoto
, Yosuke Shindo
, et al.
·
Bioorganic & Medicinal Chemistry
·
14
Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 In Vitro
2014
·
Naoki Mine
, Sayaka Yamamoto
, et al.
·
Molecular Cancer Therapeutics
·
13
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma
2024
·
T. Enzler
, A. Nguyen
, et al.
·
European Journal of Cancer
·
6
PDF
CBP501 suppresses macrophage induced cancer stem cell like features and metastases
2017
·
Naoki Mine
, Sayaka Yamamoto
, et al.
·
Oncotarget
·
6
PDF
Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts.
2020
·
Marc Ryan Matrana
, Frank Tsai
, et al.
·
Journal of Clinical Oncology
·
3
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM).
2012
·
Lee M. Krug
, Antoinette J. Wozniak
, et al.
·
Journal of Clinical Oncology
·
3
1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3
2023
·
T. Enzler
, A. Nguyen
, et al.
·
Annals of Oncology
·
2
PDF
SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity
2015
·
Janice Chen
, Christopher L. Brooks
, et al.
·
Blood
·
2
Abstract C131: CBP501 (CBP), a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) - pharmacokinetics (PK) in two phase I/II studies
2009
·
Sunil Sharma
, Raoul Tibes
, et al.
·
Molecular Cancer Therapeutics
·
2
Abstract B47: CBP501, a novel cell cycle dysregulator, in combination with cisplatin (CDDP) and pemetrexed (PM) - results of two phase I/II studies
2009
·
Sunil Sharma
, Raoul Tibes
, et al.
·
Molecular Cancer Therapeutics
·
2
ErbB1 and ErbB4 generate opposing signals regulating mesenchymal cell proliferation during valvulogenesis
2017
·
Ryo Iwamoto
, Naoki Mine
, et al.
·
Development
·
1
PDF
Binomial and Multinomial Proportions: Accurate Estimation and Reliable Assessment of Accuracy
2016
·
Friedman, Jonathan Malcolm
·
arXiv (Cornell University)
·
1
PDF
Preclinical activity of SL-801, a reversible inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) in solid and hematologic cancers.
2015
·
Janice Chen
, Christopher L. Brooks
, et al.
·
Journal of Clinical Oncology
·
1
外皮・躯体と設備・機器の総合エネルギーシミュレーションツール「best」の開発 (その157)bestとbimの連携に関する検討
2015
·
飯田 玲香
, 村上 周三
, et al.
·
1
G2 checkpoint abrogation as a cancer specific, cell cycle disruption
2005
·
Takumi Kawabe
·
Annals of Cancer Research and Therapy
·
1
PDF
Show more works
View as search
Works count:
34
Citation count:
2,611
Year
Topic
Type